These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32895941)

  • 1. Elucidating the Impact of Immunogenicity Assessment Postapproval: A Targeted Analysis of Immunogenicity Postmarketing Requirements and Commitments.
    Guinn D; Madabushi R; Wang YM; Zineh I; Maxfield K
    Clin Pharmacol Ther; 2021 Mar; 109(3):697-704. PubMed ID: 32895941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies.
    Gendy JM; Nomura N; Stuart JN; Blumenthal G
    Ther Innov Regul Sci; 2024 Mar; 58(2):380-386. PubMed ID: 38182940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence.
    Moneer O; Brown BL; Avorn J; Darrow JJ; Mitra-Majumdar M; Joyce KW; Ross M; Pham C; Kesselheim AS
    Drug Saf; 2022 Apr; 45(4):305-318. PubMed ID: 35182362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products.
    Hyogo A; Kaneko M; Narukawa M
    J Oncol Pract; 2018 Jan; 14(1):e34-e41. PubMed ID: 29136389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US FDA Postmarketing Requirements and Commitments: A Systematic Assessment of Clinical Pharmacology Studies and Their Impact on US FDA Prescribing Information.
    Ridge S; Guinn D; Pfuma Fletcher E; Zineh I; Madabushi R; Ramamoorthy A
    J Clin Pharmacol; 2023 Jun; 63(6):695-703. PubMed ID: 36731882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade.
    Younis IR; Manchandani P; Hassan HE; Qosa H
    Clin Pharmacol Ther; 2022 Sep; 112(3):635-642. PubMed ID: 35780478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation.
    Avachat C; Younis IR; Birnbaum AK
    Clin Pharmacol Ther; 2023 Dec; 114(6):1238-1242. PubMed ID: 37750407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies.
    Fan Y; Sun B; Agarwal S; Zhang L
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S193-204. PubMed ID: 27385175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing Drug-Drug Interaction Knowledge Gaps at the Time of Approval: An Analysis of FDA Postmarketing Requirements and Commitments from 2009 to 2023.
    Ridge S; Yang X; Madabushi R; Ramamoorthy A
    J Clin Pharmacol; 2024 Oct; ():. PubMed ID: 39363538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of real-world evidence to support FDA post-approval study requirements for oncology drugs.
    Zettler ME
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):657-666. PubMed ID: 35512688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
    Skydel JJ; Zhang AD; Dhruva SS; Ross JS; Wallach JD
    Clin Trials; 2021 Aug; 18(4):488-499. PubMed ID: 33863236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A descriptive analysis of postmarketing requirement studies and clinical trials.
    Choi L; Etchey B; Billings M; Lee C; Weil KM; Boxwell D; Edelberg H
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5725. PubMed ID: 37994284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory considerations for determining postmarketing study commitments.
    Meyer RJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):228-30. PubMed ID: 17538552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
    Mofid S; Bolislis WR; Kühler TC
    Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Factors Associated With Immunogenicity Labeling Updates and Characteristics of Biologics License Applications.
    Jiang AL; Breder CD; Chang LC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1381-1388. PubMed ID: 34383294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.